Progress in Hematopoietic Stem Cell Transplantation for CIDP

Authors: Qin, Z., Huang, Q. Y., Zou, J. Y., Tang, L. S., Hu, Z. P., and Tang, X. Q.

Published: International Journal of Medical Sciences  January 2020.

 Affiliations: Cent S Univ, Xiangya Hosp 2, Dept Neurol, Renmin Rd 139, Changsha 410011, Hunan, Peoples R China ; ] Healing Stem Cell Therapy Inc, POB 2289, Shawnee Mission, KS 66201 USA.

Abstract: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a kind of autoimmune-mediated inflammation and demyelinating disease. The etiology is mainly related to autoimmune dysfunction. The conventional treatments of CIDP have relied on immunomodulation and inhibition therapies such as adrenal cortex hormone, intravenous immunoglobulin (IVIg) and plasma exchange. Hematopoietic stem cell transplantation (HSCT) is known as a novel therapy for autoimmune disorders, which provides the chance to cure CIDP. More than 70 patients with refractory CIDP have received HSCT. The clinical symptoms and electrophysiological examination results of most patients have been improved. However, the treatment still has risks. This review describes the pathogenesis of CIDP and the current conventional treatments, and highlights the application of HSCT in CIDP, including its efficacy and safety.